Nuwellis, Inc. Overview
Pro stress-test →Nuwellis is a medical device company that develops, manufactures, and commercializes medical devices used in ultrafiltration therapy, specifically the Aquadex FlexFlow and Aquadex SmartFlow systems used to treat patients with fluid overload due to heart failure. The company operates at a micro-capitalization scale ($300M market cap) and serves hospitals and clinics primarily through its direct US salesforce, with international presence through specialty distributors.
Strategic Profile
Pro stress-test →Nuwellis faced headwinds in 2025 with revenue declining 5.38% to $8.27M and losses expanding to $17.52M. The company appointed Mike McCormick as CEO effective June 30, 2026, with John Erb transitioning to Chairman. Nuwellis announced a public offering of 20M shares for approximately $6M in gross proceeds in June 2026, indicating capital-raising efforts to support operations and growth initiatives.
Competitive Landscape
Pro stress-test →Nuwellis competes in the specialized ultrafiltration therapy market for treating fluid overload in cardiac patients. Primary competitors include larger medical device companies with fluid management and dialysis portfolios, including Fresenius (dialysis/renal), Baxter (fluid management), and Outset Medical (dialysis platforms). Nuwellis's differentiation lies in its portable Aquadex systems designed for acute heart failure settings and emerging pediatric applications, though it lacks the scale and distribution network of larger competitors.
Industry Context
Nuwellis, Inc. operates in Ultrafiltration therapy medical devices.
Key facts
Founded: 1999 · Headquarters: Eden Prairie, Minnesota, US · Revenue: $8.27M (2025) · Market cap: ~$300M